Effect of rHuEPO Therapy on Long-Term Survival of Children with Acute Lymphoblastic Leukemia, Undergoing Chemotherapy According to the Program ALL-BFM-90m
Methods. Thirty two patients with ALL undergoing chemotherapy according to the program ALL-BFM-90m were enrolled in clinical trial. They received rHuEPO throughout an intensive phase of chemotherapy Thirty children comparable on age and clinical manifestations were controls (without rHuEPO). The remote results were estimated according to the characteristic of 5-year event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS). Results. The 5-year EFS for patients treated with rHuEPO was 0,81 ± 0,04 compared to 0,73 ± 0,03 in control group (p = 0,51). The 5-year RFS was 0,93 ± 0,03 and 0,79 ± 0,04 in rHuEPO treated group and control group respectively (p = 0,130). The 5-year OS for patients treated with rHuEPO was 0,81 ± 0,04 compared to 0,73 ± 0,03 in control group (p = 0,35). Conclusions. Long-term survival analysis hadn't revealed negative effect of rHuEPO treatment during chemotherapy on survival of children with ALL.